Michalsen Andreas, Knoblauch Nicola T M, Lehmann Nils, Grossman Paul, Kerkhoff Gert, Wilhelm Frank H, Moebus Susanne, Konstantinides Stavros, Binder Lutz, Heusch Gerd, Siffert Winfried, Budde Thomas, Dobos Gustav J
Abteilung Innere Medizin V, Kliniken-Essen-Mitte, Germany.
Am Heart J. 2006 Apr;151(4):870-7. doi: 10.1016/j.ahj.2005.06.025.
Given the multimodal medical and interventional treatment options in coronary artery disease, the additional value of intensified lifestyle modification is unclear. We have therefore examined the effects of lifestyle modification on top of current treatment and also associated with the GNB3 C825T polymorphism, which has established association to sympathetic activation and the precipitation of angina.
One hundred one patients with established coronary artery disease were randomized to a 1-year lifestyle modification group (lifestyle group [LG]) or an advice group. Risk factors, coronary calcification (electron beam tomography), heart rate variability, baroreflex sensitivity, anginal symptoms, and quality of life (QOL) were assessed on entry and after 1 year.
Patients in LG had excellent program adherence, but lifestyle modification had no impact on metabolic risk factors and coronary calcification. Changes in heart rate, heart rate variability, and blood pressure were only slightly favoring LG. Baroreflex sensitivity increased by 2 (0.79-3.13) ms/mm Hg in the LG but decreased by -0.10 (-1.11 to 0.92) in the advice group (P = .013). Lifestyle modification led to improved physical QOL, reductions of anginal attacks (-54% vs 11%, P = .01), and dose reductions in 30% of anti-ischemic medications (P = .004). *825T allele carriers had a more pronounced reduction of heart rate and improvement of angina and QOL. The beneficial effect on reduction of medication was seen in *825T allele carriers only.
In the presence of modern treatments, comprehensive lifestyle modification provides no additional benefits on progression of atherosclerosis but improves autonomic function, angina, and QOL with concomitant reduced need of medication. These responses are more pronounced in GNB3*825T allele carriers.
鉴于冠状动脉疾病存在多种医学和介入治疗选择,强化生活方式改变的附加价值尚不清楚。因此,我们研究了在当前治疗基础上生活方式改变的效果,以及与GNB3 C825T基因多态性的关联,该基因多态性已证实与交感神经激活及心绞痛发作有关。
101例确诊为冠状动脉疾病的患者被随机分为1年生活方式改变组(生活方式组[LG])或建议组。在入组时和1年后评估危险因素、冠状动脉钙化(电子束断层扫描)、心率变异性、压力反射敏感性、心绞痛症状和生活质量(QOL)。
LG组患者对方案的依从性良好,但生活方式改变对代谢危险因素和冠状动脉钙化无影响。心率、心率变异性和血压的变化仅略微有利于LG组。LG组压力反射敏感性增加2(0.79 - 3.13)ms/mm Hg,而建议组降低 - 0.10(-1.11至0.92)(P = 0.013)。生活方式改变使身体QOL得到改善,心绞痛发作减少(-54%对11%,P = 0.01),30%的抗缺血药物剂量减少(P = 0.004)。825T等位基因携带者心率降低更明显,心绞痛和QOL改善更显著。仅在825T等位基因携带者中观察到对减少药物使用的有益效果。
在现有现代治疗的情况下,全面的生活方式改变对动脉粥样硬化进展无额外益处,但可改善自主神经功能、心绞痛和QOL,同时减少药物需求。这些反应在GNB3 *825T等位基因携带者中更为明显。